Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Roch Houot; Guillaume Cartron; Fontanet Bijou; Sophie de Guibert; Gilles A. Salles; Christophe Fruchart; Krimo Bouabdallah; Marie Maerevoet; Pierre Feugier; Steven Le Gouill; Hervé Tilly; Rene Olivier Casasnovas; Cécile Moluçon-Chabrot; Eric Van Den Neste; Pierre Zachee; Marc Andre; Christophe Bonnet; Corinne Haioun; Achiel Van Hoof; Koen Van Eygen; Lysiane Molina; Emmanuelle Nicolas-Virelizier; Philippe Ruminy; Franck Morschhauser

Journal Article

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Leukemia (2019) 33(3) 776-780

DOI: 10.1038/s41375-018-0282-y

17Citations

22Readers

Get full text

Cite

CITATION STYLE

APA

Houot, R., Cartron, G., Bijou, F., de Guibert, S., Salles, G. A., Fruchart, C., … Morschhauser, F. (2019). Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. Leukemia, 33(3), 776–780. https://doi.org/10.1038/s41375-018-0282-y

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Cite

Register to see more suggestions